Awaiting product image

Ihc – Breast Cancer Prognosis # 3a (Er, Pr, P53, Cathepsin D)

₹5,000.00

15 minutes
Categories: ,

This panel uses Immunohistochemistry (IHC) to evaluate four key markers that provide insight into breast cancer characteristics and behavior:

• ER (Estrogen Receptor) and
• PR (Progesterone Receptor): Indicate hormone sensitivity; cancers positive for these markers are more likely to respond to hormone therapy.
• p53: A tumor suppressor protein; overexpression or mutation is linked to aggressive tumors and poor prognosis.
• Cathepsin D: A proteolytic enzyme involved in tumor invasion and metastasis; elevated levels may be associated with increased tumor aggressiveness.
Together, these markers provide a more comprehensive profile of the tumor, helping guide treatment decisions and assess prognosis.

Enquiry Here

    Description

    Why It’s Done:

    This panel is recommended to:
    • Determine hormone receptor status (ER/PR) to guide hormonal therapy decisions.
    • Assess tumor aggressiveness and prognosis through p53 and Cathepsin D expression.
    • Support individualized treatment planning, especially in early or intermediate-stage breast cancer.
    • Identify patients who may require more aggressive treatment strategies based on molecular characteristics.

    Preparation:

    • No special preparation is required from the patient.
    • The test is performed on a tissue sample obtained through biopsy or surgery.
    • If a biopsy is scheduled, follow any pre-procedure instructions provided by your healthcare provider (e.g., fasting or medication guidelines).
    • Inform your doctor of all medications, supplements, and relevant medical conditions

    Related products